Refills

After the FDA’s March 2026 crackdown on compounded GLP-1s, virtually no major telehealth services still openly offer them, with most having stopped entirely or transitioned to FDA-approved commercial alternatives like Wegovy, Ozempic, and Zepbound[1][2]. However, there is one explicitly named service that has indicated it may continue providing compounded doses under specific clinical conditions, though the situation involves conflicting reports on its current status: Service Status on Compounded GLP-1s Key Details Hims & Hers Conditional/Limited Access (Disputed) Initially claimed it would continue offering personalized compounded doses for patients with specific medical needs (e.g., unavailable dosages or allergies) citing "loopholes" for incremental dosing[2][7]. However, other reports state Hims & Hers exited compounded semaglutide entirely in March 2026 after settling with Novo Nordisk and becoming an authorized Wegovy/Ozempic distributor[9][10]. Ro Stopped Ro now offers Zepbound via LillyDirect and has stopped offering compounded GLP-1s[2][5]. Noom Stopped Noom transitioned to partnering with LillyDirect for commercial Zepbound and Gifthealth for FDA-approved single-dose vials[2][5]. (Note: An older report mentioned Noom offered compounded Wegovy in May, but this was likely before the full enforcement or was a microdosing initiative that has since been superseded by commercial partnerships)[6]. Novelty/Firewall Firms Likely Active Smaller, non-prominent firms (e.g., Refills, Fifty410, Lovely Meds, Hello Cake) were explicitly named in FDA warning letters, suggesting they may still be operating or attempting to navigate regulations despite the crackdown[1][13]. Key Context for Your Decision The "Shortage" Loophole is Closed: The FDA officially declared the shortages of branded GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) as ended, removing the primary legal justification telehealth firms used for compounding identical copies[6][8]. Enforcement is Ongoing: The FDA issued an additional wave of 25 warning letters in June 2026, confirming that aggressive enforcement continues against telehealth marketing of compounded products[5]. Recommended Alternative: For reliable and safe access, experts recommend using FDA-approved options through providers like LillyDirect (via Ro), Noom (with Gifthealth), or Hims & Hers (now an authorized Wegovy distributor)[2][10]. Conclusion: If you are looking for a major, reputable telehealth platform that currently and confidently offers compounded GLP-1s, none exist in the current landscape. Hims & Hers is the only entity that previously claimed to offer a conditional exception, but recent reports suggest they have also ceased these sales. Any remaining access is likely limited to smaller, less regulated firms that have been explicitly warned by the FDA.

Mentioned in position 4 of 9